SENATE BILL 6651

State of Washington 55th Legislature 1998 Regular Session

By Senators Wood, Franklin and Winsley

Read first time 01/26/98. Referred to Committee on Health & Long-Term Care.

AN ACT Relating to electronic transfer of prescription information; amending RCW 69.41.010 and 69.50.101; adding a new section to chapter 69.41 RCW; and adding a new section to chapter 69.50 RCW.

4 BE IT ENACTED BY THE LEGISLATURE OF THE STATE OF WASHINGTON:

5 Sec. 1. RCW 69.41.010 and 1996 c 178 s 16 are each amended to read 6 as follows:

7 As used in this chapter, the following terms have the meanings 8 indicated unless the context clearly requires otherwise:

9 (1) "Administer" means the direct application of a legend drug 10 whether by injection, inhalation, ingestion, or any other means, to the 11 body of a patient or research subject by:

12 (a) A practitioner; or

13 (b) The patient or research subject at the direction of the 14 practitioner.

(2) "Deliver" or "delivery" means the actual, constructive, or
attempted transfer from one person to another of a legend drug, whether
or not there is an agency relationship.

18 (3) "Department" means the department of health.

1 (4) "Dispense" means the interpretation of a prescription or order 2 for a legend drug and, pursuant to that prescription or order, the 3 proper selection, measuring, compounding, labeling, or packaging 4 necessary to prepare that prescription or order for delivery.

(5) "Dispenser" means a practitioner who dispenses.

6 (6) "Distribute" means to deliver other than by administering or7 dispensing a legend drug.

8

5

(7) "Distributor" means a person who distributes.

9 (8) "Drug" means:

(a) Substances recognized as drugs in the official United States
pharmacopoeia, official homeopathic pharmacopoeia of the United States,
or official national formulary, or any supplement to any of them;

(b) Substances intended for use in the diagnosis, cure, mitigation,
treatment, or prevention of disease in man or animals;

(c) Substances (other than food, minerals or vitamins) intended to affect the structure or any function of the body of man or animals; and (d) Substances intended for use as a component of any article specified in clause (a), (b), or (c) of this subsection. It does not include devices or their components, parts, or accessories.

(9) "Electronic communication of prescription information" means the communication of prescription information by computer, or the transmission of an exact visual image of a prescription by facsimile, or other electronic means for original prescription information or prescription refill information for a legend drug from an authorized practitioner to a pharmacy or the transfer of prescription information for a legend drug from one pharmacy to another pharmacy.

27 (10) "Legend drugs" means any drugs which are required by state law 28 or regulation of the state board of pharmacy to be dispensed on 29 prescription only or are restricted to use by practitioners only.

30 (((10))) (11) "Person" means individual, corporation, government or 31 governmental subdivision or agency, business trust, estate, trust, 32 partnership or association, or any other legal entity.

33

(((11))) <u>(12)</u> "Practitioner" means:

(a) A physician under chapter 18.71 RCW, an osteopathic physician
or an osteopathic physician and surgeon under chapter 18.57 RCW, a
dentist under chapter 18.32 RCW, a podiatric physician and surgeon
under chapter 18.22 RCW, a veterinarian under chapter 18.92 RCW, a
registered nurse, advanced registered nurse practitioner, or licensed
practical nurse under chapter 18.79 RCW, an optometrist under chapter

1 18.53 RCW who is certified by the optometry board under RCW 18.53.010, 2 an osteopathic physician assistant under chapter 18.57A RCW, a 3 physician assistant under chapter 18.71A RCW, or a pharmacist under 4 chapter 18.64 RCW;

5 (b) A pharmacy, hospital, or other institution licensed, 6 registered, or otherwise permitted to distribute, dispense, conduct 7 research with respect to, or to administer a legend drug in the course 8 of professional practice or research in this state; and

9 (c) A physician licensed to practice medicine and surgery or a 10 physician licensed to practice osteopathic medicine and surgery in any 11 state, or province of Canada, which shares a common border with the 12 state of Washington.

13 (((12))) (13) "Secretary" means the secretary of health or the 14 secretary's designee.

15 <u>NEW SECTION.</u> Sec. 2. A new section is added to chapter 69.41 RCW 16 to read as follows:

(1) Information concerning an original prescription or information concerning a prescription refill for a legend drug may be electronically communicated to a pharmacy of the patient's choice pursuant to the provisions of this chapter if the electronically communicated prescription information complies with the following:

(a) Electronically communicated prescription information must
 comply with all applicable statutes and rules regarding the form,
 content, recordkeeping, and processing of a prescription for a legend
 drug;

(b) The system used for transmitting electronically communicated 26 prescription information and for receiving 27 the system used electronically communicated prescription information must be approved 28 29 by the board. This subsection does not apply to currently used facsimile equipment transmitting an exact visual image of the 30 The board shall maintain and provide, upon request, a 31 prescription. 32 list of systems used for electronically communicating prescription information currently approved by the board; 33

34 (c) An explicit opportunity for practitioners must be made to
 35 indicate their preference on whether a therapeutically equivalent
 36 generic drug may be substituted;

37 (d) Prescription drug orders are confidential health information,38 and may be released only to the patient or the patient's authorized

1 representative, the prescriber or other authorized practitioner then 2 caring for the patient, or other persons specifically authorized by law 3 to receive such information;

4 (e) To maintain confidentiality of prescription records, the 5 electronic system shall have adequate security and systems safequards designed to prevent and detect unauthorized access, modification, or 6 7 manipulation of these records. The pharmacist in charge shall 8 establish or verify the existence of policies and procedures which 9 ensure the integrity and confidentiality of prescription information 10 transmitted to the pharmacy by electronic means. All managers, employees, and agents of the pharmacy are required to read, sign, and 11 12 comply with the established policies and procedures; and

(f) The pharmacist shall exercise professional judgment regarding the accuracy, validity, and authenticity of the prescription drug order received by way of electronic transmission, consistent with federal and state laws and rules and guidelines of the board.

17 (2) The board may adopt rules implementing this section.

18 Sec. 3. RCW 69.50.101 and 1996 c 178 s 18 are each amended to read 19 as follows:

20 Unless the context clearly requires otherwise, definitions of terms 21 shall be as indicated where used in this chapter:

(a) "Administer" means to apply a controlled substance, whether by
 injection, inhalation, ingestion, or any other means, directly to the
 body of a patient or research subject by:

25 (1) a practitioner authorized to prescribe (or, by the 26 practitioner's authorized agent); or

(2) the patient or research subject at the direction and in thepresence of the practitioner.

(b) "Agent" means an authorized person who acts on behalf of or at the direction of a manufacturer, distributor, or dispenser. It does not include a common or contract carrier, public warehouseperson, or employee of the carrier or warehouseperson.

33 (c) "Board" means the state board of pharmacy.

(d) "Controlled substance" means a drug, substance, or immediate
 precursor included in Schedules I through V as set forth in federal or
 state laws, or federal or board rules.

(e)(1) "Controlled substance analog" means a substance the chemical
 structure of which is substantially similar to the chemical structure
 of a controlled substance in Schedule I or II and:

4 (i) that has a stimulant, depressant, or hallucinogenic effect on
5 the central nervous system substantially similar to the stimulant,
6 depressant, or hallucinogenic effect on the central nervous system of
7 a controlled substance included in Schedule I or II; or

8 (ii) with respect to a particular individual, that the individual 9 intends to have a stimulant, depressant, represents or or 10 hallucinogenic effect on the central nervous system substantially similar to the stimulant, depressant, or hallucinogenic effect on the 11 central nervous system of a controlled substance included in Schedule 12 13 I or II.

14 (2) The term does not include:

15 (i) a controlled substance;

16 (ii) a substance for which there is an approved new drug 17 application;

(iii) a substance with respect to which an exemption is in effect for investigational use by a particular person under Section 505 of the federal Food, Drug and Cosmetic Act, 21 U.S.C. Sec. 355, to the extent conduct with respect to the substance is pursuant to the exemption; or (iv) any substance to the extent not intended for human consumption before an exemption takes effect with respect to the substance.

(f) "Deliver" or "delivery," means the actual or constructive transfer from one person to another of a substance, whether or not there is an agency relationship.

27

(g) "Department" means the department of health.

(h) "Dispense" means the interpretation of a prescription or order
for a controlled substance and, pursuant to that prescription or order,
the proper selection, measuring, compounding, labeling, or packaging
necessary to prepare that prescription or order for delivery.

32

(i) "Dispenser" means a practitioner who dispenses.

33 (j) "Distribute" means to deliver other than by administering or 34 dispensing a controlled substance.

35

(k) "Distributor" means a person who distributes.

(1) "Drug" means (1) a controlled substance recognized as a drug in the official United States pharmacopoeia/national formulary or the official homeopathic pharmacopoeia of the United States, or any supplement to them; (2) controlled substances intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease in individuals or animals; (3) controlled substances (other than food) intended to affect the structure or any function of the body of individuals or animals; and (4) controlled substances intended for use as a component of any article specified in (1), (2), or (3) of this subsection. The term does not include devices or their components, parts, or accessories.

8 (m) "Drug enforcement administration" means the drug enforcement 9 administration in the United States Department of Justice, or its 10 successor agency.

11

(n) "Immediate precursor" means a substance:

(1) that the state board of pharmacy has found to be and by rule designates as being the principal compound commonly used, or produced primarily for use, in the manufacture of a controlled substance;

(2) that is an immediate chemical intermediary used or likely to beused in the manufacture of a controlled substance; and

(3) the control of which is necessary to prevent, curtail, or limitthe manufacture of the controlled substance.

(o) "Isomer" means an optical isomer, but in RCW 69.50.101(r)(5), 69.50.204(a) (12) and (34), and 69.50.206(a)(4), the term includes any geometrical isomer; in RCW 69.50.204(a) (8) and (42), and 69.50.210(c) the term includes any positional isomer; and in RCW 69.50.204(a)(35), 69.50.204(c), and 69.50.208(a) the term includes any positional or geometric isomer.

25 (p) "Manufacture" means the production, preparation, propagation, compounding, conversion, or processing of a controlled substance, 26 27 either directly or indirectly or by extraction from substances of natural origin, or independently by means of chemical synthesis, or by 28 a combination of extraction and chemical synthesis, and includes any 29 30 packaging or repackaging of the substance or labeling or relabeling of its container. The term does not include the preparation, compounding, 31 packaging, repackaging, labeling, or relabeling of a controlled 32 33 substance:

(1) by a practitioner as an incident to the practitioner's
administering or dispensing of a controlled substance in the course of
the practitioner's professional practice; or

(2) by a practitioner, or by the practitioner's authorized agent
under the practitioner's supervision, for the purpose of, or as an
incident to, research, teaching, or chemical analysis and not for sale.

(q) "Marijuana" or "marihuana" means all parts of the plant 1 2 Cannabis, whether growing or not; the seeds thereof; the resin extracted from any part of the plant; and every compound, manufacture, 3 4 salt, derivative, mixture, or preparation of the plant, its seeds or 5 resin. The term does not include the mature stalks of the plant, fiber produced from the stalks, oil or cake made from the seeds of the plant, 6 7 any other compound, manufacture, salt, derivative, mixture, or 8 preparation of the mature stalks (except the resin extracted 9 therefrom), fiber, oil, or cake, or the sterilized seed of the plant 10 which is incapable of germination.

(r) "Narcotic drug" means any of the following, whether produced directly or indirectly by extraction from substances of vegetable origin, or independently by means of chemical synthesis, or by a combination of extraction and chemical synthesis:

(1) Opium, opium derivative, and any derivative of opium or opium derivative, including their salts, isomers, and salts of isomers, whenever the existence of the salts, isomers, and salts of isomers is possible within the specific chemical designation. The term does not include the isoquinoline alkaloids of opium.

(2) Synthetic opiate and any derivative of synthetic opiate,
including their isomers, esters, ethers, salts, and salts of isomers,
esters, and ethers, whenever the existence of the isomers, esters,
ethers, and salts is possible within the specific chemical designation.
(3) Poppy straw and concentrate of poppy straw.

(4) Coca leaves, except coca leaves and extracts of coca leaves from which cocaine, ecgonine, and derivatives or ecgonine or their salts have been removed.

28 (5) Cocaine, or any salt, isomer, or salt of isomer thereof.

29 (6) Cocaine base.

30 (7) Ecgonine, or any derivative, salt, isomer, or salt of isomer 31 thereof.

32 (8) Any compound, mixture, or preparation containing any quantity33 of any substance referred to in subparagraphs (1) through (7).

(s) "Opiate" means any substance having an addiction-forming or addiction-sustaining liability similar to morphine or being capable of conversion into a drug having addiction-forming or addiction-sustaining liability. The term includes opium, substances derived from opium (opium derivatives), and synthetic opiates. The term does not include, unless specifically designated as controlled under RCW 69.50.201, the

dextrorotatory isomer of 3-methoxy-n-methylmorphinan and its salts
 (dextromethorphan). The term includes the racemic and levorotatory
 forms of dextromethorphan.

4 (t) "Opium poppy" means the plant of the species Papaver somniferum5 L., except its seeds.

6 (u) "Person" means individual, corporation, business trust, estate, 7 trust, partnership, association, joint venture, government, 8 governmental subdivision or agency, or any other legal or commercial 9 entity.

10 (v) "Poppy straw" means all parts, except the seeds, of the opium 11 poppy, after mowing.

12 (w) "Practitioner" means:

13 (1) A physician under chapter 18.71 RCW, a physician assistant under chapter 18.71A RCW, an osteopathic physician and surgeon under 14 15 chapter 18.57 RCW, a dentist under chapter 18.32 RCW, a podiatric physician and surgeon under chapter 18.22 RCW, a veterinarian under 16 17 chapter 18.92 RCW, a registered nurse, advanced registered nurse practitioner, or licensed practical nurse under chapter 18.79 RCW, a 18 19 pharmacist under chapter 18.64 RCW or a scientific investigator under 20 this chapter, licensed, registered or otherwise permitted insofar as is consistent with those licensing laws to distribute, dispense, conduct 21 research with respect to or administer a controlled substance in the 22 23 course of their professional practice or research in this state.

(2) A pharmacy, hospital or other institution licensed, registered,
 or otherwise permitted to distribute, dispense, conduct research with
 respect to or to administer a controlled substance in the course of
 professional practice or research in this state.

(3) A physician licensed to practice medicine and surgery, a physician licensed to practice osteopathic medicine and surgery, a dentist licensed to practice dentistry, a podiatric physician and surgeon licensed to practice podiatric medicine and surgery, or a veterinarian licensed to practice veterinary medicine in any state of the United States.

(x) "Prescription" means an order for controlled substances issued
 by a practitioner duly authorized by law or rule in the state of
 Washington to prescribe controlled substances within the scope of his
 or her professional practice for a legitimate medical purpose.

(y) "Production" includes the manufacturing, planting, cultivating,growing, or harvesting of a controlled substance.

(z) "Secretary" means the secretary of health or the secretary's
 designee.

3 (aa) "State," unless the context otherwise requires, means a state 4 of the United States, the District of Columbia, the Commonwealth of 5 Puerto Rico, or a territory or insular possession subject to the 6 jurisdiction of the United States.

7 (bb) "Ultimate user" means an individual who lawfully possesses a 8 controlled substance for the individual's own use or for the use of a 9 member of the individual's household or for administering to an animal 10 owned by the individual or by a member of the individual's household. (cc) "Electronic communication of prescription information" means 11 the communication of prescription information by computer, or the 12 13 transmission of an exact visual image of a prescription by facsimile, or other electronic means for original prescription information or 14 prescription refill information for a controlled substance from an 15 authorized practitioner to a pharmacy or the transfer of prescription 16 information for a controlled substance from one pharmacy to another 17 18 pharmacy.

19 <u>NEW SECTION.</u> Sec. 4. A new section is added to chapter 69.50 RCW 20 to read as follows:

(1) Information concerning an original prescription or information concerning a prescription refill for a controlled substance may be electronically communicated to a pharmacy of the patient's choice pursuant to the provisions of this chapter if the electronically communicated prescription information complies with the following:

(a) Electronically communicated prescription information must
comply with all applicable statutes and rules regarding the form,
content, recordkeeping, and processing of a prescription for a legend
drug;

30 (b) The system used for transmitting electronically communicated prescription information and used 31 the system for receiving electronically communicated prescription information must be approved 32 by the board. This subsection does not apply to currently used 33 34 facsimile equipment transmitting an exact visual image of the The board shall maintain and provide, upon request, a 35 prescription. 36 list of systems used for electronically communicating prescription 37 information currently approved by the board;

(c) An explicit opportunity for practitioners must be made to
 indicate their preference on whether a therapeutically equivalent
 generic drug may be substituted;

(d) Prescription drug orders are confidential health information,
and may be released only to the patient or the patient's authorized
representative, the prescriber or other authorized practitioner then
caring for the patient, or other persons specifically authorized by law
to receive such information;

9 (e) To maintain confidentiality of prescription records, the 10 electronic system shall have adequate security and systems safequards designed to prevent and detect unauthorized access, modification, or 11 manipulation of these records. The pharmacist in charge shall 12 establish or verify the existence of policies and procedures which 13 ensure the integrity and confidentiality of prescription information 14 15 transmitted to the pharmacy by electronic means. All managers, 16 employees, and agents of the pharmacy are required to read, sign, and 17 comply with the established policies and procedures; and

(f) The pharmacist shall exercise professional judgment regarding the accuracy, validity, and authenticity of the prescription drug order received by way of electronic transmission, consistent with federal and state laws and rules and guidelines of the board.

22 (2) The board may adopt rules implementing this section.

--- END ---